TFF Pharmaceuticals Reports Second Quarter 2020 Financial and Business Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
TFF Pharmaceuticals Inc. (TFFP) Tops Q2 EPS by 1c
August 13, 2020 4:05 PM EDTTFF Pharmaceuticals Inc. (NASDAQ: TFFP) reported Q2 EPS of ($0.20), $0.01 better than the analyst estimate of ($0.21).
TFF Pharmaceuticals accomplishments during the quarter, and in recent weeks, have truly demonstrated the capability and potential of our groundbreaking technology platform, said Glenn Mattes, President and CEO of TFF Pharmaceuticals. Most recently, our worldwide licensing agreement with UNION Therapeutics on our Thin Film Freezing technology for oral and inhalation versions of niclosamide has the potential to speed efforts to reformulate and investigate this very promising existing drug for COVID-19 therapies. It is gratifying to have our... More
